Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 605 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Functional Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function

NCT00543075
View directory record Official record
Conditions
Normal Renal Function, Mildly Impaired Renal Function, Moderately Impaired Renal Function
Interventions
Genasense (oblimersen, G3139)
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Weeks and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Oct 23, 2026, 8:15 AM EDT
Recruiting No phase listed Observational

The Impact of Renal Transplant on Coronary Microvascular Function Among Patients With Advanced Chronic Kidney Disease

NCT07222683
View directory record Official record
Conditions
Chronic Kidney Disease, Kidney Transplant, Coronary Microvascular Dysfunction (CMD), Inflammation
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 23, 2026, 8:15 AM EDT
Completed Not applicable Interventional

The Effect of Dietary Nitrates on Physical Performance and Vascular Function in Chronic Kidney Disease

NCT04103736
View directory record Official record
Conditions
Kidney Disease, Chronic, Endothelial Dysfunction
Interventions
Beet It Sport Shot, Nitrate-depleted placebo
Dietary Supplement
Lead sponsor
University of Delaware
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 23, 2026, 8:15 AM EDT
Completed No phase listed Observational Results available

HIV and Kidney Function Study

NCT00905151
View directory record Official record
Conditions
HIV Infections, AIDS
Interventions
Not listed
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 23, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02

NCT03776539
View directory record Official record
Conditions
Impaired Renal Function
Interventions
ELX-02
Drug
Lead sponsor
Eloxx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 23, 2026, 8:15 AM EDT
Terminated No phase listed Observational

Sexual Function in Male Renal Transplant Patients

NCT00271830
View directory record Official record
Conditions
Renal Transplant Recipients
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 65 Years · Male only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2007 · Synced Oct 23, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function

NCT07137689
View directory record Official record
Conditions
Renal Insufficiency
Interventions
LY3537982
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Jacksonville, Florida • Miami Lakes, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 23, 2026, 8:15 AM EDT
Completed Not applicable Interventional

Assessing Novel Methods of Improving Patient Education of Nutrition

NCT00394576
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Internet-based nutrition module along with usual care, usual care
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 90 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 23, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function

NCT06496217
View directory record Official record
Conditions
Renal Impairment
Interventions
MBX 2109
Drug
Lead sponsor
MBX Biosciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 23, 2026, 8:15 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function

NCT07763418
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Golcadomide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 84 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Chandler, Arizona • Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function

NCT03961932
View directory record Official record
Conditions
Renal Impairment, Healthy Participants
Interventions
Linzagolix
Drug
Lead sponsor
ObsEva SA
Industry
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Oct 23, 2026, 8:15 AM EDT
Terminated Phase 1Phase 2 Interventional

Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis

NCT00086164
View directory record Official record
Conditions
Hyperplasia, Chronic Renal Failure
Interventions
edifoligide (E2F Decoy)
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
21
States / cities
Los Angeles, California • Hudson, Florida • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2005 · Synced Oct 23, 2026, 8:15 AM EDT
Completed Phase 2 Interventional

Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy

NCT00664027
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
RTA 402 (Bardoxolone Methyl)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 23, 2026, 8:15 AM EDT
Completed Not applicable Interventional

Pomegranate and Hemodialysis Pilot Trial

NCT01562340
View directory record Official record
Conditions
End Stage Renal Disease, Cardiovascular Disease, Inflammation
Interventions
Pomegranate juice, Pomegranate fruit extract
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 23, 2026, 8:15 AM EDT
Completed No phase listed Observational

Use of Abbott High Sensitivity Troponin I Assay In Acute Coronary Syndromes

NCT02060760
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Troponin
Interventions
Not listed
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
1,927 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 23, 2026, 8:15 AM EDT
Terminated Phase 3 Interventional Results available

Renal Allograft Function and Histology Following Switching From A Tacrolimus to Sirolimus (SRL)-Based Immunosuppression-

NCT01166724
View directory record Official record
Conditions
Kidney Transplant
Interventions
Sirolimus, Tacrolimus
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 23, 2026, 8:15 AM EDT
Recruiting Not applicable Interventional

MediBeacon® Transdermal GFR System for the Evaluation of Kidney Function in Adults With Heart Failure

NCT07349797
View directory record Official record
Conditions
Glomerular Filtration Rate, Heart Failure
Interventions
Lumitrace, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (tGFR), Iohexol
Device · Drug
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 23, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

NCT06318676
View directory record Official record
Conditions
Renal Impairment
Interventions
Mezigdomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 82 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 23, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Aleglitazar in Combination With Aspirin in Healthy Volunteers

NCT01188304
View directory record Official record
Conditions
Healthy Volunteer
Interventions
aleglitazar, aspirin, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 23, 2026, 8:15 AM EDT
Suspended Not applicable Interventional

SCD for CRS in Congestive Heart Failure (CHF) (No Left Ventricular Assist Device)

NCT04589065
View directory record Official record
Conditions
Heart Failure, Chronic Systolic Heart Failure, Renal Failure, Cardiorenal Syndrome
Interventions
Selective Cytopheretic Device
Device
Lead sponsor
Lenar Yessayan
Other
Eligibility
21 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 23, 2026, 8:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety, and Tolerability of Methylnaltrexone (MNTX) in Subjects With Impaired Renal Function

NCT01367509
View directory record Official record
Conditions
Renal Impairment
Interventions
Methylnaltrexone (MNTX)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 23, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients

NCT00622869
View directory record Official record
Conditions
Liver Transplantation
Interventions
Tacrolimus (reduced tacrolimus), Tacrolimus (tacrolimus elimination), Tacrolimus (tacrolimus control), Everolimus (reduced tacrolimus), Everolimus (tacrolimus elimination), Corticosteroids
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 23, 2026, 8:15 AM EDT
Not listed Phase 1Phase 2 Interventional

Measurement of Eye Blood Flow and Renal Function in Healthy and Diabetic Patients

NCT01626469
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Captopril, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Oct 23, 2026, 8:15 AM EDT
Terminated Phase 4 Interventional

Dopamine in Acute Decompensated Heart Failure II

NCT01060293
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
High-dose furosemide, Low-dose furosemide, Low-dose furosemide combined with low-dose dopamine
Drug
Lead sponsor
Larissa University Hospital
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Atlanta, Georgia • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2013 · Synced Oct 23, 2026, 8:15 AM EDT